利多卡因浸润鼻腔黏膜治疗急性上呼吸道感染相关性鼻内神经痛的疗效及安全性研究  

Efficacy and Safety of the Infiltration of Nasal Mucosa With Lidocaine in the Treatment of Nasal Interal Neuralgia Related to Acute Upper Respiratory Tract Infection

作　　者：何亮亮[1] 左欣鹭 曹国庆[1] 杨立强[1] 武百山[1] 岳剑宁[1] 赖光辉[1] 郭玉娜[1] 杨惠婕[1] 唐元章[1] 倪家骧[1] 

机构地区：[1]首都医科大学宣武医院疼痛科,北京市100053 [2]承德护理职业学院

出　　处：《中国全科医学》2016年第15期1744-1748,共5页Chinese General Practice

基　　金：北京市医院管理局临床医学发展专项经费资助项目(XYLX201507)

摘　　要：目的：评估利多卡因浸润鼻腔黏膜治疗急性上呼吸道感染相关性鼻内神经痛的临床疗效及安全性。方法2014年10月—2015年12月，选取首都医科大学宣武医院符合纳入与排除标准的急性上呼吸道感染相关性鼻内神经痛患者40例为研究对象。采用随机数字表法将其分为利多卡因组（A 组）和0.9％氯化钠溶液组（B 组），各20例。分别用蘸有1％利多卡因药液和0.9％氯化钠溶液的棉签浸润 A 组和 B 组患者鼻腔黏膜，3~5 min/次，时间间隔1~3 min，共浸润5~10次。记录患者治疗前和首次治疗后即刻、1、4、7 d 总体疼痛、鼻部疼痛、眼部疼痛的疼痛视觉模拟评分法（VAS）评分，首次治疗后即刻、治疗后7 d 主诉总体疼痛、鼻部疼痛、眼部疼痛明显缓解（疼痛缓解程度≥50％）、鼻涕明显减少（鼻涕减少≥50％）的例数，接受治疗次数，满意度 VAS 评分，头晕、嗜睡等不良反应发生情况。结果治疗方法与治疗时间在总体疼痛、鼻部疼痛、眼部疼痛的 VAS 评分上存在交互作用（P ＜0.05）；治疗方法和治疗时间在总体疼痛、鼻部疼痛、眼部疼痛的 VAS 评分上主效应显著（P ＜0.05）。A 组患者治疗后4 d 总体疼痛、眼部疼痛的 VAS 评分低于 B 组（P ＜0.05）。A 组患者治疗后即刻、1、4、7 d 总体疼痛、鼻部疼痛、眼部疼痛的VAS 评分低于治疗前（P ＜0.05）；B 组患者治疗后4、7 d 总体疼痛、鼻部疼痛、眼部疼痛的 VAS 评分低于治疗前、治疗后即刻（P ＜0.05）。A 组患者治疗后即刻主诉总体疼痛、鼻部疼痛、眼部疼痛明显缓解例数多于 B 组（ P ＜0.05）；两组患者治疗后即刻主诉鼻涕明显减少，治疗后7 d 主诉总体疼痛、鼻部疼痛、眼部疼痛明显缓解、鼻涕明显减少的例数比较，差异无统计学意义（P ＞0.05）。A 组患者治疗后7 d 主诉鼻涕明显减少例数多于治疗后即刻（ P ＜0.05�Objective To investigate the clinical efficacy and safety of the infiltration of nasal mucosa with lidocaine in the treatment of nasal interal neuralgia related to acute upper respiratory tract infection. Methods From October 2014 to December 2015,we enrolled 40 patients with nasal interal neuralgia related to acute upper respiratory tract infection who accorded with the inclusion and exclusion criteria from Xuanwu Hospital Capital Medical University as research subjects. Using random number table method,we divided the patients into two groups：lidocaine group（group A）and 0. 9% sodium chloride solution＆amp;nbsp;（group B）,and each group had 20 patients. Group A and group B received infiltration of nasal mucosa with 1% lidocaine and 0. 9% sodium chloride solution respectively every 1 - 3 minutes for 5 - 10 times with 3 - 5 minutes per time. The VAS scores of general pain,nasal pain and ocular pain before treatment,immediately after first treatment,and on day 1,4 and 7 were recorded;the numbers of patients with obvious（≥50% ）remission of general pain,nasal pain and ocular pain and obvious （≥50% ）decrease in nasal mucus immediately after treatment and 7 days after treatment,times of treatment,VAS score of satisfaction and adverse reactions such as dizziness and drowsiness were recorded. Results The interaction was identified between treatment and time on VAS scores of general pain,nasal pain and ocular pain（P 〈 0. 05）. Main effects of treatment and time on VAS scores of general pain,nasal pain and ocular pain were significant（P 〈 0. 05）. Group A was lower than group B in VAS scores of general pain and ocular pain on day 4 after treatment（P 〈 0. 05）. Group A had lower VAS scores of general pain, nasal pain and ocular pain immediately after treatment and on day 1,4 and 7 after treatment than those before treatment（P 〈0. 05）;group B had lower VAS scores of general pain,nasal pain and ocular pain on day 4 and 7 after treatment than those before treatment and immediately afte

关 键 词：利多卡因 呼吸道感染 神经痛 治疗结果 

分 类 号：R765.64[医药卫生—耳鼻咽喉科]